Cargando…

The mRNA-1273 Vaccine Induces Cross-Variant Antibody Responses to SARS-CoV-2 With Distinct Profiles in Individuals With or Without Pre-Existing Immunity

mRNA-based vaccines effectively induce protective neutralizing antibodies against SARS-CoV-2, the etiological agent of COVID-19. Yet, the kinetics and compositional patterns of vaccine-induced antibody responses to the original strain and emerging variants of concern remain largely unknown. Here we...

Descripción completa

Detalles Bibliográficos
Autores principales: Tejedor Vaquero, Sonia, de Campos-Mata, Leire, Ramada, José María, Díaz, Pilar, Navarro-Barriuso, Juan, Ribas-Llaurado, Clara, Rodrigo Melero, Natalia, Carolis, Carlo, Cerutti, Andrea, Gimeno, Ramon, Magri, Giuliana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8446508/
https://www.ncbi.nlm.nih.gov/pubmed/34539673
http://dx.doi.org/10.3389/fimmu.2021.737083
_version_ 1784568893589684224
author Tejedor Vaquero, Sonia
de Campos-Mata, Leire
Ramada, José María
Díaz, Pilar
Navarro-Barriuso, Juan
Ribas-Llaurado, Clara
Rodrigo Melero, Natalia
Carolis, Carlo
Cerutti, Andrea
Gimeno, Ramon
Magri, Giuliana
author_facet Tejedor Vaquero, Sonia
de Campos-Mata, Leire
Ramada, José María
Díaz, Pilar
Navarro-Barriuso, Juan
Ribas-Llaurado, Clara
Rodrigo Melero, Natalia
Carolis, Carlo
Cerutti, Andrea
Gimeno, Ramon
Magri, Giuliana
author_sort Tejedor Vaquero, Sonia
collection PubMed
description mRNA-based vaccines effectively induce protective neutralizing antibodies against SARS-CoV-2, the etiological agent of COVID-19. Yet, the kinetics and compositional patterns of vaccine-induced antibody responses to the original strain and emerging variants of concern remain largely unknown. Here we characterized serum antibody classes and subclasses targeting the spike receptor-binding domain of SARS-CoV-2 wild type and α, β, γ and δ variants in a longitudinal cohort of SARS-CoV-2 naïve and COVID-19 recovered individuals receiving the mRNA-1273 vaccine. We found that mRNA-1273 vaccine recipients developed a SARS-CoV-2-specific antibody response with a subclass profile comparable to that induced by natural infection. Importantly, these antibody responses targeted both wild type SARS-CoV-2 as well as its α, β, γ and δ variants. Following primary vaccination, individuals with pre-existing immunity showed higher induction of all antibodies but IgG3 compared to SARS-CoV-2-naïve subjects. Unlike naïve individuals, COVID-19 recovered subjects did not mount a recall antibody response upon the second vaccine dose. In these individuals, secondary immunization resulted in a slight reduction of IgG1 against the receptor-binding domain of β and γ variants. Despite the lack of recall humoral response, vaccinees with pre-existing immunity still showed higher titers of IgG1 and IgA to all variants analyzed compared to fully vaccinated naïve individuals. Our findings indicate that mRNA-1273 vaccine triggered cross-variant antibody responses with distinct profiles in vaccinees with or without pre-existing immunity and suggest that individuals with prior history of SARS-CoV-2 infection may not benefit from the second mRNA vaccine dose with the current standard regimen.
format Online
Article
Text
id pubmed-8446508
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-84465082021-09-18 The mRNA-1273 Vaccine Induces Cross-Variant Antibody Responses to SARS-CoV-2 With Distinct Profiles in Individuals With or Without Pre-Existing Immunity Tejedor Vaquero, Sonia de Campos-Mata, Leire Ramada, José María Díaz, Pilar Navarro-Barriuso, Juan Ribas-Llaurado, Clara Rodrigo Melero, Natalia Carolis, Carlo Cerutti, Andrea Gimeno, Ramon Magri, Giuliana Front Immunol Immunology mRNA-based vaccines effectively induce protective neutralizing antibodies against SARS-CoV-2, the etiological agent of COVID-19. Yet, the kinetics and compositional patterns of vaccine-induced antibody responses to the original strain and emerging variants of concern remain largely unknown. Here we characterized serum antibody classes and subclasses targeting the spike receptor-binding domain of SARS-CoV-2 wild type and α, β, γ and δ variants in a longitudinal cohort of SARS-CoV-2 naïve and COVID-19 recovered individuals receiving the mRNA-1273 vaccine. We found that mRNA-1273 vaccine recipients developed a SARS-CoV-2-specific antibody response with a subclass profile comparable to that induced by natural infection. Importantly, these antibody responses targeted both wild type SARS-CoV-2 as well as its α, β, γ and δ variants. Following primary vaccination, individuals with pre-existing immunity showed higher induction of all antibodies but IgG3 compared to SARS-CoV-2-naïve subjects. Unlike naïve individuals, COVID-19 recovered subjects did not mount a recall antibody response upon the second vaccine dose. In these individuals, secondary immunization resulted in a slight reduction of IgG1 against the receptor-binding domain of β and γ variants. Despite the lack of recall humoral response, vaccinees with pre-existing immunity still showed higher titers of IgG1 and IgA to all variants analyzed compared to fully vaccinated naïve individuals. Our findings indicate that mRNA-1273 vaccine triggered cross-variant antibody responses with distinct profiles in vaccinees with or without pre-existing immunity and suggest that individuals with prior history of SARS-CoV-2 infection may not benefit from the second mRNA vaccine dose with the current standard regimen. Frontiers Media S.A. 2021-09-03 /pmc/articles/PMC8446508/ /pubmed/34539673 http://dx.doi.org/10.3389/fimmu.2021.737083 Text en Copyright © 2021 Tejedor Vaquero, de Campos-Mata, Ramada, Díaz, Navarro-Barriuso, Ribas-Llaurado, Rodrigo Melero, Carolis, Cerutti, Gimeno and Magri https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Tejedor Vaquero, Sonia
de Campos-Mata, Leire
Ramada, José María
Díaz, Pilar
Navarro-Barriuso, Juan
Ribas-Llaurado, Clara
Rodrigo Melero, Natalia
Carolis, Carlo
Cerutti, Andrea
Gimeno, Ramon
Magri, Giuliana
The mRNA-1273 Vaccine Induces Cross-Variant Antibody Responses to SARS-CoV-2 With Distinct Profiles in Individuals With or Without Pre-Existing Immunity
title The mRNA-1273 Vaccine Induces Cross-Variant Antibody Responses to SARS-CoV-2 With Distinct Profiles in Individuals With or Without Pre-Existing Immunity
title_full The mRNA-1273 Vaccine Induces Cross-Variant Antibody Responses to SARS-CoV-2 With Distinct Profiles in Individuals With or Without Pre-Existing Immunity
title_fullStr The mRNA-1273 Vaccine Induces Cross-Variant Antibody Responses to SARS-CoV-2 With Distinct Profiles in Individuals With or Without Pre-Existing Immunity
title_full_unstemmed The mRNA-1273 Vaccine Induces Cross-Variant Antibody Responses to SARS-CoV-2 With Distinct Profiles in Individuals With or Without Pre-Existing Immunity
title_short The mRNA-1273 Vaccine Induces Cross-Variant Antibody Responses to SARS-CoV-2 With Distinct Profiles in Individuals With or Without Pre-Existing Immunity
title_sort mrna-1273 vaccine induces cross-variant antibody responses to sars-cov-2 with distinct profiles in individuals with or without pre-existing immunity
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8446508/
https://www.ncbi.nlm.nih.gov/pubmed/34539673
http://dx.doi.org/10.3389/fimmu.2021.737083
work_keys_str_mv AT tejedorvaquerosonia themrna1273vaccineinducescrossvariantantibodyresponsestosarscov2withdistinctprofilesinindividualswithorwithoutpreexistingimmunity
AT decamposmataleire themrna1273vaccineinducescrossvariantantibodyresponsestosarscov2withdistinctprofilesinindividualswithorwithoutpreexistingimmunity
AT ramadajosemaria themrna1273vaccineinducescrossvariantantibodyresponsestosarscov2withdistinctprofilesinindividualswithorwithoutpreexistingimmunity
AT diazpilar themrna1273vaccineinducescrossvariantantibodyresponsestosarscov2withdistinctprofilesinindividualswithorwithoutpreexistingimmunity
AT navarrobarriusojuan themrna1273vaccineinducescrossvariantantibodyresponsestosarscov2withdistinctprofilesinindividualswithorwithoutpreexistingimmunity
AT ribasllauradoclara themrna1273vaccineinducescrossvariantantibodyresponsestosarscov2withdistinctprofilesinindividualswithorwithoutpreexistingimmunity
AT rodrigomeleronatalia themrna1273vaccineinducescrossvariantantibodyresponsestosarscov2withdistinctprofilesinindividualswithorwithoutpreexistingimmunity
AT caroliscarlo themrna1273vaccineinducescrossvariantantibodyresponsestosarscov2withdistinctprofilesinindividualswithorwithoutpreexistingimmunity
AT ceruttiandrea themrna1273vaccineinducescrossvariantantibodyresponsestosarscov2withdistinctprofilesinindividualswithorwithoutpreexistingimmunity
AT gimenoramon themrna1273vaccineinducescrossvariantantibodyresponsestosarscov2withdistinctprofilesinindividualswithorwithoutpreexistingimmunity
AT magrigiuliana themrna1273vaccineinducescrossvariantantibodyresponsestosarscov2withdistinctprofilesinindividualswithorwithoutpreexistingimmunity
AT tejedorvaquerosonia mrna1273vaccineinducescrossvariantantibodyresponsestosarscov2withdistinctprofilesinindividualswithorwithoutpreexistingimmunity
AT decamposmataleire mrna1273vaccineinducescrossvariantantibodyresponsestosarscov2withdistinctprofilesinindividualswithorwithoutpreexistingimmunity
AT ramadajosemaria mrna1273vaccineinducescrossvariantantibodyresponsestosarscov2withdistinctprofilesinindividualswithorwithoutpreexistingimmunity
AT diazpilar mrna1273vaccineinducescrossvariantantibodyresponsestosarscov2withdistinctprofilesinindividualswithorwithoutpreexistingimmunity
AT navarrobarriusojuan mrna1273vaccineinducescrossvariantantibodyresponsestosarscov2withdistinctprofilesinindividualswithorwithoutpreexistingimmunity
AT ribasllauradoclara mrna1273vaccineinducescrossvariantantibodyresponsestosarscov2withdistinctprofilesinindividualswithorwithoutpreexistingimmunity
AT rodrigomeleronatalia mrna1273vaccineinducescrossvariantantibodyresponsestosarscov2withdistinctprofilesinindividualswithorwithoutpreexistingimmunity
AT caroliscarlo mrna1273vaccineinducescrossvariantantibodyresponsestosarscov2withdistinctprofilesinindividualswithorwithoutpreexistingimmunity
AT ceruttiandrea mrna1273vaccineinducescrossvariantantibodyresponsestosarscov2withdistinctprofilesinindividualswithorwithoutpreexistingimmunity
AT gimenoramon mrna1273vaccineinducescrossvariantantibodyresponsestosarscov2withdistinctprofilesinindividualswithorwithoutpreexistingimmunity
AT magrigiuliana mrna1273vaccineinducescrossvariantantibodyresponsestosarscov2withdistinctprofilesinindividualswithorwithoutpreexistingimmunity